• Co-Founder John Konstantopoulos appointed as Chief Executive Officer
• Harvey Farrington appointed as Acting Chief Financial Officer
• Bernie Ridgeway becomes Executive Chair to support company's evolution

Artrya Limited, a medical technology company commercializing its Salix AI-powered cloud platform for the assessment and management of coronary artery disease, has announced a leadership transition effective July 1, 2025. Co-Founder John Konstantopoulos will be appointed as the new Chief Executive Officer, replacing Mat Regan who has made significant contributions over the past two years. Harvey Farrington, the current Global Commercial Manager, will take on the role of Acting Chief Financial Officer, and Bernie Ridgeway, the current Non-Executive Chair, will become the Executive Chair. These changes are part of Artrya's evolution and preparation for the planned U.S. commercialization. Konstantopoulos, with his strong clinical and commercial expertise, as well as deep knowledge of Artrya's technology, strategy, and stakeholders, is well-positioned to lead the company through this next phase of growth. Farrington, a Chartered Accountant with extensive experience in strategic commercial and financial roles, will support the business growth and execution. Ridgeway, with his extensive listed company corporate and commercial experience, will provide guidance and support in his new role as Executive Chair. The leadership transition marks an exciting new chapter for Artrya as it focuses on commercial growth, execution, and deeper engagement with clinical and commercial partners.

Artrya is focused on commercial growth and execution, with a deeper engagement with clinical and commercial partners to address the global need for real-time, point-of-care diagnostic solutions for coronary artery disease.